Standard Dosing Schedule for Keytruda
Keytruda (pembrolizumab) is administered as an intravenous infusion every 3 weeks or every 6 weeks, depending on the approved indication, patient weight, and treatment duration. The standard dose is 200 mg every 3 weeks or 400 mg every 6 weeks for adults.[1][2]
How Dosing Varies by Cancer Type
Dosing aligns with FDA-approved indications:
- Most solid tumors (e.g., melanoma, non-small cell lung cancer, head and neck cancer): 200 mg IV every 3 weeks or 400 mg every 6 weeks, up to 2 years or disease progression.[1]
- MSI-H/dMMR cancers or endometrial carcinoma: Same schedule, often combined with other drugs like lenvatinib.[1]
- Pediatric patients (for certain relapsed/refractory solid tumors): 2 mg/kg (up to 200 mg) every 3 weeks.[1]
Treatment stops after 35 doses (about 2 years) for many regimens unless progression occurs.[2]
Why Every 3 or 6 Weeks?
Keytruda's half-life of about 23 days supports less frequent dosing. The 6-week option (400 mg) provides equivalent exposure to three 3-week doses (200 mg each), offering scheduling flexibility while maintaining efficacy in trials like KEYNOTE-024 and KEYNOTE-189.[2][3]
What If a Dose Is Missed?
Administer the missed dose as soon as possible, then resume the original schedule. Do not double doses. For 3-week regimens, if delayed over 3 weeks, restart as new cycle.[2]
Common Side Effects Tied to Infusion Frequency
Fatigue, nausea, and immune-related issues (e.g., colitis, pneumonitis) occur regardless of schedule, but frequent infusions increase clinic visits. Monitor thyroid, liver, and lung function every 3-6 weeks.[1][2]
Adjustments for Patient Factors